King Gets Inventories Under Control; Next Step Is Boosting Brand Sales
Executive Summary
King Pharmaceuticals has dramatically reduced wholesale inventory levels and associated product return rates this year, the company said during its Nov. 9 third quarter earnings call
You may also be interested in...
King’s Best Price Settlement Covers Entire Product Portfolio
King's settlement of charges that it failed to properly calculate Medicaid best price rebates is far larger than most such settlements because it includes the company's entire portfolio
King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans
King will not pursue a new merger partner following the collapse of its proposed agreement to be acquired by Mylan
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011